Opinion|Videos|April 25, 2024

Treatment Selection in Metastatic and Castration Resistant Prostate Cancer: Optimizing Outcomes and Preserving Patient Quality of Life

Drs. Shore & McKay discuss treatment selection for metastatic & castration-resistant prostate cancer, the current landscape, and key factors guiding personalized treatment decisions.

Episodes in this series

Video 1 - "Metastatic Prostate Cancer: Background and Patient Prognosis"

EP. 1 Metastatic Prostate Cancer: Background and Patient Prognosis

Video 2 - "Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer"

EP. 2 Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer

Video 3 - "Treatment Selection in Metastatic and Castration Resistant Prostate Cancer: Optimizing Outcomes and Preserving Patient Quality of Life"

EP. 3 Treatment Selection in Metastatic and Castration Resistant Prostate Cancer: Optimizing Outcomes and Preserving Patient Quality of Life

Video 4 - "Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis"

EP. 4 Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis

Video 5 - "Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer"

EP. 5 Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer

Video 6 - "Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape"

EP. 6 Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape

Video 7 - "Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer"

EP. 7 Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Precision Medicine and Patient Selection in mHSPC

ByScott Sellinger, MD, FACS

August 20th 2026

Bringing POTOMAC Data Into Community Urology Practice for High-Risk NMIBC

ByNeal D. Shore, MD, FACS,Chandler Park, MD

August 19th 2026

POTOMAC Subgroup Data: Cystectomy Risk and Rare Adverse Events in NMIBC

ByNeal D. Shore, MD, FACS,Chandler Park, MD

August 19th 2026

Managing Immune-Related Adverse Events With Durvalumab Plus BCG in NMIBC

ByNeal D. Shore, MD, FACS,Chandler Park, MD

August 19th 2026

Inside the POTOMAC Trial: Durvalumab Plus BCG for High-Risk NMIBC

ByNeal D. Shore, MD, FACS,Chandler Park, MD

August 19th 2026

Latest CME

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom

FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy

Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care